VERTEX PHARMACEUTICALS INC (VRTX) Stock Overview
USA - NASDAQ:VRTX - US92532F1003 - Common Stock
VRTX Key Statistics, Chart & Performance
The current stock price of VRTX is 419.475 USD. In the past month the price increased by 9.24%. In the past year, price decreased by -11.79%.
VRTX Latest News, Press Relases and Analysis
VRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.51 | 402.33B | ||
| AMGN | AMGEN INC | 13.26 | 155.74B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 148.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.47B | ||
| ARGX | ARGENX SE - ADR | 89.53 | 50.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.46B | ||
| INSM | INSMED INC | N/A | 34.24B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.29 | 18.87B |
Related stock screener links
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VRTX FAQ
What does VRTX do?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Can you provide the latest stock price for VERTEX PHARMACEUTICALS INC?
The current stock price of VRTX is 419.475 USD. The price decreased by -0.45% in the last trading session.
Does VRTX stock pay dividends?
VRTX does not pay a dividend.
How is the ChartMill rating for VERTEX PHARMACEUTICALS INC?
VRTX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists VRTX stock?
VRTX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for VERTEX PHARMACEUTICALS INC?
VERTEX PHARMACEUTICALS INC (VRTX) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of VRTX stock?
VERTEX PHARMACEUTICALS INC (VRTX) has a market capitalization of 107.55B USD. This makes VRTX a Large Cap stock.
VRTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to VRTX. When comparing the yearly performance of all stocks, VRTX is a bad performer in the overall market: 82.01% of all stocks are doing better.
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to VRTX. Both the health and profitability get an excellent rating, making VRTX a very profitable company, without any liquidiy or solvency issues.
VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of 16.94. The EPS increased by 7966.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.86% | ||
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0 |
VRTX Forecast & Estimates
39 analysts have analysed VRTX and the average price target is 490.23 USD. This implies a price increase of 16.87% is expected in the next year compared to the current price of 419.475.
For the next year, analysts expect an EPS growth of 6237.82% and a revenue growth 10.07% for VRTX